Swiss spine surgery company Neo Medical has commercially launched the Neo Instant MIS Access platform in the US.
The platform is designed for posterior thoracic, lumbar, and sacral minimally invasive surgery (MIS) procedures, with the company positioning it as a solution to several operational barriers that have limited wider adoption of MIS approaches.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It enables adaptive, scalable MIS capabilities in any surgical spine facility.
Neo Medical stated that the system does not require capital investment, can be prepared in under two minutes, and may reduce operational costs per procedure by up to $2,500 compared to conventional MIS access methods, based on internal value models cited by the company.
The platform is intended to help facilities with high turnover by increasing operating room throughput and procedural capacity.
Conventional access to MIS frequently relies on factors such as capital equipment, reusable instrument stocks, table-mounted systems, reprocessing cycles, vendor logistics, and workflow management. These elements can hinder scalability in hospitals and ambulatory surgery centres (ASCs).
The platform has been designed to remove these barriers.
Neo Medical co-founder and CEO Vincent Lefauconnier said: “The future of minimally invasive spine surgery is no longer defined by surgical technique alone. It is defined by how efficiently healthcare systems can deliver those procedures at scale.
“We believe the next frontier in MIS adoption is operational simplicity, and Instant MIS Access was designed specifically to address that challenge.”
The company indicated that further international launches, including in Europe, are planned following relevant regulatory processes.
Neo Medical develops technologies focused on reducing procedural complexity and supporting reproducibility in spine surgery.
In September 2024, the company raised $68m in a Series B funding round to expand its portfolio of surgical technologies across the US.
